WO2000067788A3 - Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires - Google Patents

Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires Download PDF

Info

Publication number
WO2000067788A3
WO2000067788A3 PCT/US2000/012435 US0012435W WO0067788A3 WO 2000067788 A3 WO2000067788 A3 WO 2000067788A3 US 0012435 W US0012435 W US 0012435W WO 0067788 A3 WO0067788 A3 WO 0067788A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune responses
costimulatory molecules
enhance immune
soluble costimulatory
molecules
Prior art date
Application number
PCT/US2000/012435
Other languages
English (en)
Other versions
WO2000067788A2 (fr
Inventor
Knut Sturmhoefel
Stanley F Wolf
Margot O'toole
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00930437A priority Critical patent/EP1181053A2/fr
Priority to JP2000616813A priority patent/JP2002544170A/ja
Priority to CA002373256A priority patent/CA2373256A1/fr
Priority to PL36091500A priority patent/PL360915A1/xx
Priority to BR0010711-5A priority patent/BR0010711A/pt
Priority to KR1020017014170A priority patent/KR20020001865A/ko
Application filed by Genetics Inst filed Critical Genetics Inst
Priority to IL14610600A priority patent/IL146106A0/xx
Priority to AU48257/00A priority patent/AU4825700A/en
Publication of WO2000067788A2 publication Critical patent/WO2000067788A2/fr
Publication of WO2000067788A3 publication Critical patent/WO2000067788A3/fr
Priority to NO20015396A priority patent/NO20015396L/no
Priority to HK02102335.8A priority patent/HK1041810A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Cette invention concerne des méthodes propres à favoriser des réponses immunitaires, selon lesquelles on administre des formes solubles de molécules de co-stimulation, telles que des molécules B7, pour accroître les réponses immunitaires à des antigènes tels que des cellules tumorales ou des agents infectieux. Les méthodes selon l'invention conviennent à titre tant prophylactique et thérapeutique pour l'immunisation de sujets.
PCT/US2000/012435 1999-05-06 2000-05-05 Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires WO2000067788A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2000616813A JP2002544170A (ja) 1999-05-06 2000-05-05 免疫応答を高めるための可溶性同時刺激分子の使用
CA002373256A CA2373256A1 (fr) 1999-05-06 2000-05-05 Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires
PL36091500A PL360915A1 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
BR0010711-5A BR0010711A (pt) 1999-05-06 2000-05-05 Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
KR1020017014170A KR20020001865A (ko) 1999-05-06 2000-05-05 면역반응을 증강시키기 위한 가용성 공동자극 분자의 용도
EP00930437A EP1181053A2 (fr) 1999-05-06 2000-05-05 Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires
IL14610600A IL146106A0 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
AU48257/00A AU4825700A (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
NO20015396A NO20015396L (no) 1999-05-06 2001-11-05 Anvendelse av löselige kostimulerende molekyler for å forsterke immunresponser
HK02102335.8A HK1041810A1 (zh) 1999-05-06 2002-03-26 增加免疫反應的可溶性共同刺激分子的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06
US60/132,944 1999-05-06

Publications (2)

Publication Number Publication Date
WO2000067788A2 WO2000067788A2 (fr) 2000-11-16
WO2000067788A3 true WO2000067788A3 (fr) 2001-04-05

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012435 WO2000067788A2 (fr) 1999-05-06 2000-05-05 Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires

Country Status (15)

Country Link
EP (1) EP1181053A2 (fr)
JP (1) JP2002544170A (fr)
KR (1) KR20020001865A (fr)
CN (1) CN1377279A (fr)
AU (1) AU4825700A (fr)
BR (1) BR0010711A (fr)
CA (1) CA2373256A1 (fr)
CZ (1) CZ20013964A3 (fr)
HK (1) HK1041810A1 (fr)
HU (1) HUP0201222A3 (fr)
IL (1) IL146106A0 (fr)
NO (1) NO20015396L (fr)
PL (1) PL360915A1 (fr)
WO (1) WO2000067788A2 (fr)
ZA (1) ZA200109376B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
EP1910387B1 (fr) * 2005-06-30 2016-11-16 Eisai R&D Management Co., Ltd. Composes pour la preparation d'un adjuvant immunologique
MX2008007287A (es) 2005-12-08 2008-10-27 Univ Louisville Res Found Metodos y composiciones para expandir celulas reguladoras t.
MX2008007286A (es) 2005-12-08 2008-10-21 Univ Louisville Res Found Ingenieria in vivo de superficie celular.
US9511151B2 (en) * 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
AU2012290306B2 (en) * 2011-07-29 2017-08-17 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20150056232A1 (en) * 2012-04-02 2015-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP3065771B1 (fr) 2013-11-04 2019-03-20 UTI Limited Partnership Méthodes et compositions d'immunothérapie soutenue
SG10201913957PA (en) 2015-05-06 2020-03-30 Uti Lp Nanoparticle compositions for sustained therapy
CN110743006B (zh) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 用于协同解除免疫细胞衰竭的组合物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006605A2 (fr) * 1998-07-28 2000-02-10 Micromet Ag Heterominicorps

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006605A2 (fr) * 1998-07-28 2000-02-10 Micromet Ag Heterominicorps

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN AOSHUANG ET AL: "Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors.", FEBS LETTERS, vol. 428, no. 3, 29 May 1998 (1998-05-29), pages 127 - 134, XP002154489, ISSN: 0014-5793 *
MORO MONICA ET AL: "Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.", CANCER RESEARCH, vol. 59, no. 11, 1 June 1999 (1999-06-01), pages 2650 - 2656, XP002154490, ISSN: 0008-5472 *
RAO JAY B ET AL: "IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression.", JOURNAL OF IMMUNOLOGY, vol. 156, no. 9, 1996, pages 3357 - 3365, XP002154488, ISSN: 0022-1767 *
RENNERT PAUL ET AL: "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.", INTERNATIONAL IMMUNOLOGY, vol. 9, no. 6, 1997, pages 805 - 813, XP000971089, ISSN: 0953-8178 *

Also Published As

Publication number Publication date
CA2373256A1 (fr) 2000-11-16
NO20015396L (no) 2002-01-02
IL146106A0 (en) 2002-07-25
WO2000067788A2 (fr) 2000-11-16
PL360915A1 (en) 2004-09-20
KR20020001865A (ko) 2002-01-09
CN1377279A (zh) 2002-10-30
CZ20013964A3 (cs) 2002-06-12
BR0010711A (pt) 2002-02-13
HUP0201222A3 (en) 2004-07-28
HUP0201222A2 (en) 2002-08-28
AU4825700A (en) 2000-11-21
EP1181053A2 (fr) 2002-02-27
ZA200109376B (en) 2003-03-13
HK1041810A1 (zh) 2002-07-26
NO20015396D0 (no) 2001-11-05
JP2002544170A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
WO2000067788A3 (fr) Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires
WO1999033868A3 (fr) Vaccin
WO1999010375A3 (fr) Vaccin
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO2002102299A3 (fr) Procedes et compositions pharmaceutiques permettant la falsification immunitaire, particulierement utiles pour le traitement du cancer
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
WO2001060402A3 (fr) Vaccin antigrippal a base de proteosomes
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
WO2005037190A3 (fr) Vaccins multiplex
AUPN015794A0 (en) Variants of human papilloma virus antigens
HUP0402067A2 (hu) Oltóanyagok
AU2002347404A1 (en) In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
PL351893A1 (en) Vaccines
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
HUP0401753A3 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
EP2368575A3 (fr) Formulation seche pour immunisation transcutanee
WO1999050303A3 (fr) Complexe d'alpha-2 macroglobuline modulateur de la reponse immunitaire
EP1115418A4 (fr) Produits aglyco et utilisation de ceux-ci
WO2001079259A8 (fr) Complexation d'antigenes proteiques et de proteines de stress par sequence javelot
CA2232344A1 (fr) Composition et procedes permettant d'accentuer les reponses immunitaires dues aux cellules presentatrices d'antigene
WO2005000884A8 (fr) Conjugues d'acide poly-gamma-glutamique pour solliciter des reponses immunitaires dirigees contre des bacilles
WO2005025497A3 (fr) Epitopes des lymphocytes t hpv cd8+
WO2002054073A3 (fr) Modele de tuberculose humaine latente, antigenes diagnostiques et methodes d'utilisation associees
WO2002076485A3 (fr) Vaccin assurant la modulation entre des reponses immunitaires t1 et t2
WO2000061766A3 (fr) Vaccin anticancereux specifique de la telomerase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011130

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2001-3964

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2373256

Country of ref document: CA

Ref country code: CA

Ref document number: 2373256

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616813

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020017014170

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 515410

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001/09376

Country of ref document: ZA

Ref document number: 200109376

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 48257/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000930437

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008100381

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020017014170

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000930437

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-3964

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-3964

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000930437

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017014170

Country of ref document: KR